Celecoxib Versus Diclofenac In The Treatment Of Osteoarthritis Of The Hip

NCT ID: NCT00174317

Last Updated: 2006-12-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

250 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-08-31

Study Completion Date

2005-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine if celecoxib 200 mg once daily is as effective as diclofenac 50 mg three times daily in the treatment of pain symptoms associated with osteoarthritis of the hip

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoarthritis, Hip

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Celecoxib

Intervention Type DRUG

Diclofenac

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed with osteoarthritis of hip and requiring joint replacement
* Eligible for chronic therapy with an NSAID

Exclusion Criteria

* Hip surgery anticipated within 8 calendar weeks after first visit
* Active gastrointestinal disease or recent diagnosis of gastrointestinal ulceration (within 60 days of first visit)
Minimum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Aston Clinton, Bucks, United Kingdom

Site Status

Pfizer Investigational Site

Ely, Cambs, United Kingdom

Site Status

Pfizer Investigational Site

St Austell, Cornwall, United Kingdom

Site Status

Pfizer Investigational Site

Lancaster, England, United Kingdom

Site Status

Pfizer Investigational Site

Sheffield, England, United Kingdom

Site Status

Pfizer Investigational Site

Newport, Gwent, United Kingdom

Site Status

Pfizer Investigational Site

Chingford, London, United Kingdom

Site Status

Pfizer Investigational Site

Harrow, MIDDLESEX, United Kingdom

Site Status

Pfizer Investigational Site

Greenisland, Carrickfergus, Northern Ireland, United Kingdom

Site Status

Pfizer Investigational Site

Oxford, Oxon, United Kingdom

Site Status

Pfizer Investigational Site

Greenock, Renfrewshire, United Kingdom

Site Status

Pfizer Investigational Site

Barry, South Glamorgan, United Kingdom

Site Status

Pfizer Investigational Site

Barnsley, South Yorkshire, United Kingdom

Site Status

Pfizer Investigational Site

Ashford, Surrey, United Kingdom

Site Status

Pfizer Investigational Site

Newcastle upon Tyne, Tyne & Wear, United Kingdom

Site Status

Pfizer Investigational Site

Trowbridge, Wiltshire, United Kingdom

Site Status

Pfizer Investigational Site

Aberdeen, , United Kingdom

Site Status

Pfizer Investigational Site

Amersham, , United Kingdom

Site Status

Pfizer Investigational Site

Bath, , United Kingdom

Site Status

Pfizer Investigational Site

Bath, , United Kingdom

Site Status

Pfizer Investigational Site

Belfast, , United Kingdom

Site Status

Pfizer Investigational Site

Bradford, , United Kingdom

Site Status

Pfizer Investigational Site

Cardiff, , United Kingdom

Site Status

Pfizer Investigational Site

Carshalton, , United Kingdom

Site Status

Pfizer Investigational Site

Chertsey, , United Kingdom

Site Status

Pfizer Investigational Site

Edinburgh, , United Kingdom

Site Status

Pfizer Investigational Site

Glasgow, , United Kingdom

Site Status

Pfizer Investigational Site

Lancaster, , United Kingdom

Site Status

Pfizer Investigational Site

Leystonstone, London, , United Kingdom

Site Status

Pfizer Investigational Site

Liverpool, , United Kingdom

Site Status

Pfizer Investigational Site

Liverpool, , United Kingdom

Site Status

Pfizer Investigational Site

London, , United Kingdom

Site Status

Pfizer Investigational Site

Manchester, , United Kingdom

Site Status

Pfizer Investigational Site

Northampton, , United Kingdom

Site Status

Pfizer Investigational Site

Norwich, , United Kingdom

Site Status

Pfizer Investigational Site

Nuneaton, , United Kingdom

Site Status

Pfizer Investigational Site

Peterborough, , United Kingdom

Site Status

Pfizer Investigational Site

Sheffield, , United Kingdom

Site Status

Pfizer Investigational Site

Southampton, , United Kingdom

Site Status

Pfizer Investigational Site

Truro, , United Kingdom

Site Status

Pfizer Investigational Site

Wansford, , United Kingdom

Site Status

Pfizer Investigational Site

Watford, , United Kingdom

Site Status

Pfizer Investigational Site

Westbury, , United Kingdom

Site Status

Pfizer Investigational Site

Wigan, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

COXA-0508-261

Identifier Type: -

Identifier Source: org_study_id